PREDICTION OF AN OUTCOME OF A BLADDER CANCER SUBJECT

The invention relates to a method of predicting an outcome of a bladder cancer subject, comprising determining or receiving the result of a determination of gene expression profile comprising three or more expression levels selected from, immune defense response genes selected from the group consist...

Full description

Saved in:
Bibliographic Details
Main Authors HOFFMANN, Ralf Dieter, DHARMADHIKARI, Gitanjali
Format Patent
LanguageEnglish
French
German
Published 27.03.2024
Subjects
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a method of predicting an outcome of a bladder cancer subject, comprising determining or receiving the result of a determination of gene expression profile comprising three or more expression levels selected from, immune defense response genes selected from the group consisting of: AIM2, APOBEC3A, CIAO1, DDX58, DHX9, IFI16, IFIH1, IFIT1, IFIT3, LRRFIP1, MYD88, OAS1, TLR8, and ZBP1, and/or T-Cell receptor signalling genes selected from the group consisting of: CD2, CD247, CD28, CD3E, CD3G, CD4, CSK, EZR, FYN, LAT, LCK, PAG1, PDE4D, PRKACA, PRKACB, PTPRC, and ZAP70 and/or PDE4D7 correlated genes selected from the group consisting of: ABCC5, CUX2, KIAA1549, PDE4D, RAP1GAP2, SLC39A11, TDRD1, and VWA2, said gene expression profiles being determined in a biological sample obtained from the subject, and determining the prediction of the outcome based on the gene expression profile.
Bibliography:Application Number: EP20220196480